drugset / Trial / NCT06741722
Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML
NaSingle-groupOpen-labelTreatment
Summary
The DCMG regimen includes decitabine or azacitidine (hypomethylating agents), mitoxantrone liposome, cytarabine, and granulocyte colony-stimulating factor (G-CSF), comprising four medications. This project initiates a prospective and exploratory clinical study on the DCMG chemotherapy regimen for the treatment of relapsed/refractory AML (Acute Myeloid Leukemia). The study aims to evaluate the efficacy and safety of the DCMG combination chemotherapy regimen in treating relapsed/refractory AML.
Timeline
- Start
- 2024-10-31
- Primary completion
- 2026-10-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 10 mg | Intravenous |
| Subject | Cytarabine | Small molecule | 100 mg | Intravenous |
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |
| Background | Mitoxantrone | Small molecule | 15 mg/m2 | Intravenous |
| Background | Pegylated Recombinant Human Granulocyte Stimulating Factor | Protein / enzyme biologic | 100 ug/kg | Subcutaneous |